WOBURN, Mass., April 30, 2020 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies […]
Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized ensifentrineReported positive efficacy and safety with […]
Two accepted abstracts will be presented virtually in a prerecorded poster presentationMONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) — Celyad (Euronext […]